The Central Consumer Protection Authority (CCPA) has passed final orders against Dikshant IAS and Abhimanu IAS, imposing a penalty of Rs 8,00,000 each for indulging in "misleading advertisements, ...

The US Food and Drug Administration’s Office of Prescription Drug Promotion (OPDP) sent two warning letters earlier this week for misleading advertisements. One of the warnings was sent to Salt Lake ...

FIRST ON FOX: Shortly after announcing a strategy to go after deceptive direct-to-consumer advertising by the pharmaceutical industry, Robert F. Kennedy Jr. and the Department of Health and Human ...

Federal officials are cracking down on jewelers who may be guilty of false advertising. The Federal Trade Commission sent official warnings to eight online jewelry companies. The companies advertise ...

Companies’ false advertisements and other deceptive business practices can have significant adverse commercial consequences for their competitors. Along with short-term loss of business, misleading ...

Add Yahoo as a preferred source to see more of our stories on Google. FDA Warns 30 Telehealth Firms On Compounded GLP-1 Claims Image by DX The U.S. Food and Drug Administration has issued warning ...

Office of Prescription Drug Promotion (OPDP) has stepped up its enforcement efforts regarding prescription drug promotion, ...

Companies can sue for false advertising in various circumstances. If your company is facing revenue losses due to a competitor’s false or misleading statements or omissions in its advertisements, it ...

This Monday, the head of the Federal Consumer Prosecutor's Office (Profeco), Ricardo Sheffield, reported that the agency is already proceeding legally against four companies for 'misleading ...

Regulators claim Pfizer’s ads created a misleading impression by describing Adcetris as a treatment for broader T-cell lymphoma populations than those covered by its FDA-approved label. The FDA also ...

The FDA has issued 30 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs. Regulators say some companies implied their compounded products were equivalent to ...